|
Ronald Reisler, MD, MPH
Assistant Professor of Medicine UM SOM IHV Clinical Trials Unit
Assistant Director Adult AIDS Clinical Trials Group
UMD investigator HIV Vaccine Trials Network
UMD Medical Officer
B.A. - Chemistry, Harvard University, Cambridge, MA, 1987.
MPH - Epidemiology, Columbia University, New York, NY, 1989.
MD - University of Chicago, Chicago, IL, 1993.
Residency - Medicine, Rush-Presbyterian-St. Lukes, Chicago, IL, 1996.
Fellowship - Infectious Diseases, Emory University, Atlanta, GA,
1999.
Email: reisler@umbi.umd.edu
PROFILE:
Dr. Reisler is an active faculty member contributing to clinical care,
teaching, and clinical research. He currently provides both in-patient
and out-patient clinical care to HIV infected individuals at the
University of Maryland Medical Center. He played an instrumental role in
assisting the IHV in becoming fully integrated into the NIH sponsored
Adult AIDS Clinical Trials Group (AACTG) and actively participates on
numerous AACTG protocol teams and committees. Also, he has assumed a
leadership role as a primary investigator for an institute sponsored
clinical research trial with a focus on treatment experienced patients
with multi drug resistant virus. In addition, he is an investigator in
the Institute's Solid Organ Transplantation in HIV protocol which is a
multi-site protocol sponsored by the NIH.
Previously, Dr. Reisler worked as a medical officer at the National
Institutes of Health, National Institute of Allergy and Infectious
Diseases, Division of AIDS, Therapeutics Research Program, HIV Research
Branch, Bethesda, Maryland. While at NIH, he worked closely with the
three primary therapeutic clinical trials networks, the AACTG, the Terry
Beirn Community Programs for Clinical Research on AIDS (CPCRA), and the
Acute HIV Infection and Early Disease Research Program (AIEDRP). Also,
while at NIH, he received Staff Recognition Awards both in 2000 and 2001
and served on the DAIDS Preclinical Therapeutics Development Committee
(DPTDC), the NIH Inter-Institute AIDS Drug Discovery & Development
Committee, and the NIAID Working Group on Antimicrobial Resistance-
making recommendations to the joint CDC/NIH/FDA Anti Microbial
Resistance Task Force.
Dr. Reisler has authored and co-authored a number of publications and
abstracts and serves as a reviewer for the journal AIDS, JAIDS, and
Pharmacoepidemiology and Drug Safety. He is a member of the Infectious
Diseases Society of America and the American Society for Microbiology.
He is board certified in Internal Medicine and Infectious Diseases.
RESEARCH INTERESTS
- HIV Clinical Trials- Therapeutic and Vaccines
- Developing new therapeutic approaches to HIV patients with
multidrug resistant virus
- Quantifying antiretroviral therapy related toxicities
- Assessing the impact of co-morbidities in patients with HIV
- Developing clinical research that is relevant and acceptable to
the US minority and underserved populations
- Studying HIV therapeutics in the international arena
- Gaining a better understanding of the interplay of renal disease
and HIV disease and devising appropriate treatment strategies for
this population.
RECENT PUBLICATIONS:
Reisler RB and Blumberg H. "Community-Acquired Pseudomonas
stutzeri Vertebral Osteomyelitis in a Previously Healthy Patient: Case
Report and Review." Clinical Infectious Diseases: 1999: 29: 667-9.
Reisler RB, Thea DM, Pliner V, Green T, Lee F, Nesheim S, Brown
T, Kalish M, Folks TM, and Heneine W. "Early Detection of Reverse
Transcriptase Activity in Plasma of Neonates Infected with HIV-1: A
comparative analysis of RNA- and DNA- based PCR testing." JAIDS:
2001:26: 93-102.
Lawrence J, Mayers DL, Huppler-Hullsiek K, Collins G, Abrams DI,
Reisler RB, et al. Structured Treatment Interruption in Patients with
Multidrug-Resistant Human Immunodeficiency Virus. N. Engl.J. Med.
2003:349:837-846.
Bartlett JA, Tebas P, Bassett R, Huang W, Kuritzkes D, Reisler R,
et al. Early Intensification with abacavir in subjects at high risk for
incomplete viral suppression. Antiviral Therapy. 2003:8:361-363.
Reisler RB, Han C, Burman WJ, Tedaldi EM, and Neaton JD. "Grade 4 Events
are as important as AIDS events in the Era of HAART." J Acquir Immune
Defic Syndr 2003; 34:379-386.
 Back to Primary Faculty
To contact us:
Phone: 410-706-7560
Fax: 410-706-4619
E-mail: kvardjan@ihv.umaryland.edu
 Back to Top of Page
|
